Use of genetic polymorphisms to predict drug-induced hepatotoxicity

Details for Australian Patent Application No. 2004283234 (hide)

Owner Novartis AG

Inventors McCullough, Karen; Wolfgang, Curt Douglas

Agent Davies Collison Cave

Pub. Number AU-B-2004283234

PCT Pub. Number WO2005/040415

Priority 60/508,972 06.10.03 US

Filing date 5 October 2004

Wipo publication date 6 May 2005

Acceptance publication date 30 August 2007

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

13 April 2006 PCT application entered the National Phase

  PCT publication WO2005/040415 Priority application(s): WO2005/040415

30 August 2007 Application Accepted

  Published as AU-B-2004283234

3 January 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004283235-Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease

2004283229-Process for making low surfactant, high sugar bars